Dana-Farber Cancer Institute has received $10 million from the Rossy Foundation to establish the David Liposarcoma Research Initiative.
The five-year initiative will spearhead research into liposarcoma at Dana-Farber and external collaborating partner institutions, with the aim of transforming the treatment of this rare, underfunded, and understudied disease in order to improve care of patients through research.
This commitment from The Rossy Foundation will focus on collaborative research among various departments at Dana-Farber—including liposarcoma biology, biochemistry, immunology, metabolism, genomics, and epigenetics.
The overall research initiative will be led by George Demetri, director of the Sarcoma Center, senior vice president for Experimental Therapeutics, and Quick Family Chair in Medical Oncology at Dana-Farber.
The David Liposarcoma Research Initiative collaboration brings together the teams of 11 principal investigators from four institutions—Dana-Farber, Harvard Medical School, Brigham and Women’s Hospital, and the Broad Institute of MIT and Harvard. These investigators will work togeth
Dana-Farber will be the lead and coordinating institution for this new initiative.
The initiative will also include engagement of a panel comprising the international scientific advisory board. The commitment also establishes the David Liposarcoma Research Initiative International Scientific Symposium in basic, translational, and clinical liposarcoma research.
This symposium will enable the team to share results, guide the development of clinical trials in years three through five, and have a global influence to stimulate new collaborations in this field.
